Jacob Redmond
Well-Known Member
A University of Alabama at Birmingham committee has given approval to the state-authorized study of a marijuana-derived medicine to treat severe seizure in children and adults under the banner known as Carly's Law.
UAB spokesman Bob Shepard said in an email today the university's Institutional Review Board for Human Use, also known as the IRB, "has approved the protocol for the studies."
The approval signed and issued today by the IRB is seen as a major step in reaching the point to begin the trial study, which awaits permission from the U.S. Drug Enforcement Administration.
"The next step is to complete DEA requirements, which are dependent on the final approval from IRB," Shepard said. "That process is moving forward now, but we do not yet know the timetable for that step. We are getting closer."
The IRB's approval generated praise from supporters including Dustin Chandler, who was the primary driving force behind the Carly's Law legislation that is named after the 3-year-old special-needs daughter he has with his wife, Amy Chandler.
"The important thing for the IRB approving it is it's another big step forward for the state of Alabama and we're getting closer for giving people another option for treatment," Dustin Chandler said today. "Patience is the hardest virtue to master in this whole thing."
The UAB-led study will use a specialized form of marijuana-derived cannabidiol, often referred to as CBD, in children and adults with severe seizure disorders. There will be no charge for patients to participate in the study and use the medicine, which does not contain the intoxicating properties associated with marijuana.
Just last month, on Dec. 10, UAB received an approval letter from the Food and Drug Administration concerning Carly's Law. The approval arrived one day after Chandler complained about red tape in the matter before the Alabama Legislature.
Chandler is optimistic about the DEA approving the study. "Personally I don't see the DEA not accepting the study due to the fact that the other federal agency, the FDA, has approved it," he said.
According to UAB's IRB website, the committee's "purpose is to help protect the rights and welfare of human participants in research conducted under the auspices of the University of Alabama at Birmingham."
"University policy requires that all research involving human subjects be reviewed and approved by the UAB IRB before the research begins," according to the committee's website.
News Moderator: Jacob Redmond 420 MAGAZINE ®
Full Article: Carly's Law study of marijuana-based CBD medicine gets approval from UAB committee | AL.com
Author: Alabama Local News - al.com
Contact: mreed@al.com
Photo Credit: Martin J. Reed
Website: Alabama Local News - al.com
UAB spokesman Bob Shepard said in an email today the university's Institutional Review Board for Human Use, also known as the IRB, "has approved the protocol for the studies."
The approval signed and issued today by the IRB is seen as a major step in reaching the point to begin the trial study, which awaits permission from the U.S. Drug Enforcement Administration.
"The next step is to complete DEA requirements, which are dependent on the final approval from IRB," Shepard said. "That process is moving forward now, but we do not yet know the timetable for that step. We are getting closer."
The IRB's approval generated praise from supporters including Dustin Chandler, who was the primary driving force behind the Carly's Law legislation that is named after the 3-year-old special-needs daughter he has with his wife, Amy Chandler.
"The important thing for the IRB approving it is it's another big step forward for the state of Alabama and we're getting closer for giving people another option for treatment," Dustin Chandler said today. "Patience is the hardest virtue to master in this whole thing."
The UAB-led study will use a specialized form of marijuana-derived cannabidiol, often referred to as CBD, in children and adults with severe seizure disorders. There will be no charge for patients to participate in the study and use the medicine, which does not contain the intoxicating properties associated with marijuana.
Just last month, on Dec. 10, UAB received an approval letter from the Food and Drug Administration concerning Carly's Law. The approval arrived one day after Chandler complained about red tape in the matter before the Alabama Legislature.
Chandler is optimistic about the DEA approving the study. "Personally I don't see the DEA not accepting the study due to the fact that the other federal agency, the FDA, has approved it," he said.
According to UAB's IRB website, the committee's "purpose is to help protect the rights and welfare of human participants in research conducted under the auspices of the University of Alabama at Birmingham."
"University policy requires that all research involving human subjects be reviewed and approved by the UAB IRB before the research begins," according to the committee's website.
News Moderator: Jacob Redmond 420 MAGAZINE ®
Full Article: Carly's Law study of marijuana-based CBD medicine gets approval from UAB committee | AL.com
Author: Alabama Local News - al.com
Contact: mreed@al.com
Photo Credit: Martin J. Reed
Website: Alabama Local News - al.com
